Quirin Manz

Quirin Manz

Auto-generated profile, based on publicly available information

Quirin Manz

Data Science in Systems Biology, TUM School of Life Sciences, Technical University of Munich , Freising

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2024 in Nucleic Acids Research
Verified
Journal Article
Open access
AMAndreas Maier
Andreas Maier
MHMichael Hartung
Michael Hartung
MAMark Abovsky
Mark Abovsky
KAKlaudia Adamowicz
Klaudia Adamowicz
GBGary Bader
Gary Bader
Jan BaumbachJan Baumbach
Jan Baumbach
In recent decades, the development of new drugs has become increasingly expensive and inefficient, and the molecular mechanisms of most pharmaceuticals remain poorly understood. In response, computational systems and network medicine tools have emerged to identify potential drug repurposing candidates. However, these tools often require complex installation and lack intuitive visual network mining capabilities. To tackle these challenges, we introduce Drugst.One, a platform that assists specialized computational medicine tools in becoming user-friendly, web-based utilities for drug repurposing. With just three lines of code, Drugst.One turns any systems biology software into an interactive web tool for modeling and analyzing complex protein-drug-disease networks. Demonstrating its broad adaptability, Drugst.One has been successfully integrated with 21 computational systems medicine tools. Available at https://drugst.one, Drugst.One has significant potential for streamlining the drug discovery process, allowing researchers to focus on essential aspects of pharmaceutical treatment research.

25 October 2024 in Cell Host & Microbe
Verified
Journal Article
Open access
DHDeborah Häcker
Deborah Häcker
KSKolja Siebert
Kolja Siebert
BSByron J. Smith
Byron J. Smith
NKNikolai Koehler
Nikolai Koehler
ARAlessandra Riva
Alessandra Riva
DHDirk Haller
Dirk Haller
Exclusive enteral nutrition (EEN) is a first-line therapy for pediatric Crohn's disease (CD), but protective mechanisms remain unknown. We established a prospective pediatric cohort to characterize the function of fecal microbiota and metabolite changes of treatment-naive CD patients in response to EEN (German Clinical Trials DRKS00013306). Integrated multi-omics analysis identified network clusters from individually variable microbiome profiles, with Lachnospiraceae and medium-chain fatty acids as protective features. Bioorthogonal non-canonical amino acid tagging selectively identified bacterial species in response to medium-chain fatty acids. Metagenomic analysis identified high strain-level dynamics in response to EEN. Functional changes in diet-exposed fecal microbiota were further validated using gut chemostat cultures and microbiota transfer into germ-free Il10-deficient mice. Dietary model conditions induced individual patient-specific strain signatures to prevent or cause inflammatory bowel disease (IBD)-like inflammation in gnotobiotic mice. Hence, we provide evidence that EEN therapy operates through explicit functional changes of temporally and individually variable microbiome profiles.

14 September 2023 in Proteomics
Verified
Journal Article
Open access
DHDennis Hecker
Dennis Hecker
MLMichael Lauber
Michael Lauber
FAFatemeh Behjati Ardakani
Fatemeh Behjati Ardakani
SAShamim Ashrafiyan
Shamim Ashrafiyan
QMQuirin Manz
Quirin Manz
MLMarkus List
Markus List
Transcription factors (TFs) are essential players in orchestrating the regulatory landscape in cells. Still, their exact modes of action and dependencies on other regulatory aspects remain elusive. Since TFs act cell type‐specific and each TF has its own characteristics, untangling their regulatory interactions from an experimental point of view is laborious and convoluted. Thus, there is an ongoing development of computational tools that estimate transcription factor activity (TFA) from a variety of data modalities, either based on a mapping of TFs to their putative target genes or in a genome‐wide, gene‐unspecific fashion. These tools can help to gain insights into TF regulation and to prioritize candidates for experimental validation. We want to give an overview of available computational tools that estimate TFA, illustrate examples of their application, debate common result validation strategies, and discuss assumptions and concomitant limitations.

27 February 2021 in Bioinformatics
Verified
Journal Article
Closed access
PDF file
QMQuirin Manz
Quirin Manz
OTOlga Tsoy
Olga Tsoy
AFAmit Fenn
Amit Fenn
JBJan Baumbach
Jan Baumbach
UVUwe Völker
Uwe Völker
TKTim Kacprowski
Tim Kacprowski
Summary: A plethora of tools exist for RNA-Seq data analysis with a focus on alternative splicing (AS). However, appropriate data for their comparative evaluation is missing. The R package ASimulatoR simulates gold standard RNA-Seq datasets with fine-grained control over the distribution of AS events, which allow for evaluating alternative splicing tools, e.g. to study the effect of sequencing depth on the performance of AS event detection. Availability and implementation: ASimulatoR is freely available at https://github.com/biomedbigdata/ASimulatoR as an R package under GPL-3 license.

31 August 2025 in European Heart Journal
Verified
Journal Article
Closed access
KKKilian Kirmes
Kilian Kirmes
JHJiaying Han
Jiaying Han
MKMelissa Klug
Melissa Klug
CBConor J Bloxham
Conor J Bloxham
OBOlena Babyak
Olena Babyak
DBDario Bongiovanni
Dario Bongiovanni
Background and Aims: Reticulated platelets (RPs), hyperreactive and RNA-rich, are associated with increased risk of cardiovascular events and suboptimal response to antiplatelet therapy in coronary artery disease (CAD). However, the underlying mechanisms remain poorly defined. This study aimed to characterise the molecular and functional phenotype of RPs in CAD and assess their potential as therapeutic targets. Methods: RPs and mature platelets (MPs) were isolated from CAD patients based on RNA content and CD41 expression. Paired RP vs MP comparisons were conducted within each donor. Transcriptomic profiling (RNA-seq) was integrated with high-dimensional proteomics (mass cytometry) and validated in independent cohorts. Functional studies, including flow cytometry-based platelet-platelet binding, in vitro thrombosis, platelet spreading, and intracellular phospho-protein profiling, assessed the impact of PI3K and GPVI pathways. Results were curated in Platlas, an open-access interactive web resource. Results: Among 95 CAD patients, RPs exhibited elevated activation marker expression and enrichment of prothrombotic pathways compared to MPs. RNA-seq revealed upregulation of GP6, TBXA2R, and VWF transcripts, novel GPVI splicing, and RP-specific non-coding RNAs including novel circRNAs. Proteomic and functional assays confirmed heightened PI3K and GPVI signalling, with increased phosphorylation of AKT, PI3K, and SYK, and elevated reactive oxygen species production. RPs showed increased aggregation, spreading and greater recruitment in thrombus formation, which were significantly reduced by PI3K (LY294002) and GPVI (glenzocimab) inhibition. Conclusions: This study provides the first mechanistic explanation for RP hyperreactivity, revealing a distinct molecular profile and identifying GPVI and PI3K inhibition as promising targets for tailored antiplatelet therapy in CAD patients with elevated RPs.

26 June 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
QMQuirin Manz
Quirin Manz
MBMisha Bilenky
Misha Bilenky
DHDennis Hecker
Dennis Hecker
NANihit Aggarwal
Nihit Aggarwal
JGJuliana Estefania Arcila Galvis
Juliana Estefania Arcila Galvis
MHMartin Hirst
Martin Hirst
The sequence of the human genome provides a foundation for understanding cellular processes in health and disease. The organisation of this primary genetic information into cell-specific structure and function is critical to understanding the cell type-specific interpretation and execution of the genome. Epigenetic processes are essential for packaging and higher-level functional organisation of the genome, and changes therein are increasingly recognised as contributors to human disease. Building on primary data generated by multinational consortia, the International Human Epigenome Consortium (IHEC) has uniformly processed a collection of more than 2000 comprehensive human reference epigenomes, collectively referred to as EpiATLAS. This effort involved the development of standardised molecular and bioinformatics protocols, metadata models, and analytical tools to manage, integrate, display, and share vast amounts of epigenomic data. This includes the creation of a publicly available Epigenome Reference Registry, which provides a system for accessing protected human subject datasets and facilitates open searching of de-identified samples and experimental data. The integrated EpiATLAS ecosystem and its comprehensive human reference epigenome maps provide an unprecedented resource for the biosciences, expanding the annotated epigenomic landscape while uncovering previously unappreciated relationships among regulatory layers and revealing how epigenetic inputs underpin fundamental cellular functions and disease associations.